Ann Oncol: Patients with limited-stage small cell lung cancer (LD-SCLC) treated with nivolumab and ipilimumab after concurrent chemoradiotherapy + PCI can not improve the prognosis of patients

Concurrent radiotherapy and chemotherapy plus preventive craniocerebral irradiation (PCI) is the standard treatment for limited-stage small cell lung cancer (LD-SCLC), but the 5-year overall survival rate (OS) is only 25%-33%
.
Therefore, some investigators have launched a phase II study ETOP/IFCT 4-12 STIMULI to evaluate the efficacy of nivolumab+ipilimumab treatment in patients with limited-stage small cell lung cancer (LD-SCLC) after concurrent radiotherapy and chemotherapy + PCI

.

Concurrent radiotherapy and chemotherapy plus preventive craniocerebral irradiation (PCI) is the standard treatment for limited-stage small cell lung cancer (LD-SCLC), but the 5-year overall survival rate (OS) is only 25%-33%

The STIMULI study is a 1:1 randomized phase II trial designed to prove the superiority of intensive combined immunotherapy after concurrent chemoradiotherapy + PCI in patients with limited-stage small cell lung cancer (LD-SCLC) over observation

.

The STIMULI study is a 1:1 randomized phase II trial designed to prove the superiority of intensive combined immunotherapy after concurrent chemoradiotherapy + PCI in patients with limited-stage small cell lung cancer (LD-SCLC) over observation

From December 2015 to April 2019, a total of 222 patients were enrolled, and 153 patients were randomly assigned to treatment, of which 78 were combined immunotherapy and 75 were in the observation group

At the time of the data cut-off, 82 patients (53.

PFS difference between the two groups

PFS difference between the two groups

Differences in PFS between the two subgroups

Differences in PFS between the two subgroups

OS was updated on June 3, 2021, with a median follow-up time of 35.

0 months (IQR: 25.

OS was updated on June 3, 2021, with a median follow-up time of 35.

Differences in OS between the two groups

Differences in OS between the two groups

Differences in OS between the two subgroups

Differences in OS between the two subgroups

The ORR of the treatment group was 38% (95% CI: 26%-50%; 26 patients), the ORR of the observation group was 7% (95% CI: 34%-60%); while the ORR of the observation group and the experimental group No bit DoR was reached

.

The ORR of the treatment group was 38% (95% CI: 26%-50%; 26 patients), the ORR of the observation group was 7% (95% CI: 34%-60%); while the ORR of the observation group and the experimental group No bit DoR was reached

98.

AEs

AEs

In summary, studies have shown that patients with limited-stage small cell lung cancer (LD-SCLC) treated with nivolumab and ipilimumab combined with intensive treatment after concurrent chemoradiation plus PCI cannot improve the prognosis of patients

.

In summary, studies have shown that patients with limited-stage small cell lung cancer (LD-SCLC) treated with nivolumab and ipilimumab combined with intensive treatment after concurrent chemoradiation plus PCI cannot improve the prognosis of patients
.
Studies have shown that patients with limited-stage small cell lung cancer (LD-SCLC) treated with nivolumab and ipilimumab after concurrent chemoradiotherapy and PCI can not improve the prognosis of patients
.
Studies have shown that patients with limited-stage small cell lung cancer (LD-SCLC) treated with nivolumab and ipilimumab after concurrent chemoradiotherapy and PCI can not improve the prognosis of patients
.

 

Original source:

Original source:

Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G , Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruysscher D; ETOP /IFCT 4-12 STIMULI Collaborators.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy-results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Ann Oncol.
2022 Jan;33 (1):67-79.
doi: 10.
1016/j.
annonc.
2021.
09.
011.
Epub 2021 Sep 23.
PMID: 34562610.

Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, Andrade J, Becker A, Moro-Sibilot D, Curioni-Fontecedro A, Molinier O, Nackaerts K, Insa Mollá A, Gervais R, López Vivanco G , Madelaine J, Mazieres J, Faehling M, Griesinger F, Majem M, González Larriba JL, Provencio Pulla M, Vervita K, Roschitzki-Voser H, Ruepp B, Mitchell P, Stahel RA, Le Pechoux C, De Ruysscher D; ETOP /IFCT 4-12 STIMULI Collaborators.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy-results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Ann Oncol.
2022 Jan;33 (1):67-79.
doi: 10.
1016/j.
annonc.
2021.
09.
011.
Epub 2021 Sep 23.
PMID: 34562610.
Leave a message here